Healios K.K.

OTCPK:HLOS.F Stock Report

Market Cap: US$336.4m

Healios K.K Management

Management criteria checks 2/4

Healios K.K's CEO is Hardy Kagimoto, appointed in Feb 2012, has a tenure of 14.08 years. directly owns 20.61% of the company’s shares, worth $69.36M. The average tenure of the management team and the board of directors is 7.5 years and 8 years respectively.

Key information

Hardy Kagimoto

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure14.1yrs
CEO ownership20.6%
Management average tenure7.5yrs
Board average tenure8yrs

Recent management updates

Recent updates


CEO

Hardy Kagimoto (49 yo)

14.1yrs
Tenure

Dr. Tadahisa S. Kagimoto, also known as Hardy, MD, serves as Chairman, Chief Executive Officer and President of Aqumen Biopharmaceuticals, K.K. He served as Director of Athersys, Inc. since June 18, 2018 u...


Leadership Team

NamePositionTenureCompensationOwnership
Tadahisa S. Kagimoto
Chairman14.1yrsno data20.61%
$ 69.4m
Richard P. Kincaid
Executive Officer6.7yrsno data0.14%
$ 467.3k
Hironobu Kimura
Executive Officer & Head of Kobe Research Institute7.5yrsno datano data
7.5yrs
Average Tenure
49yo
Average Age

Experienced Management: HLOS.F's management team is seasoned and experienced (7.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Tadahisa S. Kagimoto
Chairman14.1yrsno data20.61%
$ 69.4m
Richard P. Kincaid
Executive Officer8yrsno data0.14%
$ 467.3k
Glenn J. Gormley
Independent Outside Director4yrsno datano data
Seigo Kashii
Independent External Director8yrsno data0.00015%
$ 504.7
Yuko Yogo
Independent Outside Director4yrsno datano data
8.0yrs
Average Tenure
68yo
Average Age

Experienced Board: HLOS.F's board of directors are considered experienced (8 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/22 20:11
End of Day Share Price 2026/03/20 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Healios K.K. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Steven SeedhouseCantor Fitzgerald & Co.
Hidemaru YamaguchiCitigroup Inc
Akinori UedaGoldman Sachs